ImmunoCellular (IMUC) has also announced that it has filed with the US patent office the two principal applications covering its multiple antigen dendritic cell cancer vaccine and cancer stem cell vaccine technologies that were the subject of provisional patent applications previously filed with the US patent office.
IMUC is currently funding a Phase I trial of the first technology, and is evaluating certain pre-clinical data for its cancer stem-cell vaccine technology to assess the feasibility of initiating a clinical development program for this technology in the treatment of brain tumors.
John Yu, chairman of the board, IMUC, said: “We are pleased that Kirk Peacock has agreed to serve on an interim basis as our president. We have launched an aggressive search to hire a full-time CEO with expertise and a proven track record of success in managing an early-stage biopharmaceutical company like ours.”